Objective: Conventional or minimally invasive surgical mitral valve repair (MVR) is the gold-standard treatment for severe mitral regurgitation (MR) of any etiology. Given its good safety profile, trans-catheter MVR with the MitraClip TM device is used increasingly for high-risk or inoperable patients. We report our experience with failed MitraClip TM therapy and its impact on subsequent surgical strategies, such as the feasibility of MVR in high-risk patients. Methods: During a follow-up of 344 AE 227 days from the first 215 consecutive patients treated with the MitraClip TM device, six patients required surgical re-intervention due to failed repair (n = 3) or recurrent severe MR (n = 3) at 35.8 AE 47.7 (range 0-117) days after trans-catheter MVR. Feasibility of secondary surgical MVR was assessed with regard to prior clip therapy. Results: In three patients, secondary surgical MVR was successfully performed following the surgical strategy deemed optimal before trans-catheter treatment. Injury of the mitral leaflets caused by prior clip treatment was present in three other patients and influenced the surgical strategy toward more complex surgical techniques in one case and MV replacement in two others. One patient died 6 days after MV replacement. All other patients are alive with adequate valve function at the latest follow-up of 12.4 AE 7.4 months (range 4-22). Conclusions: Secondary surgical MVR was feasible in some patients after prior clip treatment, but led to valve replacement in others. At present, patient selection criteria for trans-catheter MVR should not be expanded toward more healthy patients, as primary trans-catheter MVR may complicate secondary surgery in certain cases and may even preclude reconstructive valve surgery. #
Introduction
Traditionally, surgical mitral valve repair (MVR) is considered the reference treatment for degenerative disease. In elective patients, it can be carried out with perioperative mortality rates of close to 0% and extremely low complication rates [1] . If performed in a timely fashion, successful valve repair restores both life expectancy and quality of life to normal. Furthermore, at specialized centers, a minimally invasive videoscopic approach via a right-anterior minithoracotomy has been established as the standard of care [2] , offering additional benefits in terms of postoperative reconvalescence, transfusion requirements, or cosmesis.
In functional mitral regurgitation (MR), however, the pathophysiology is more complex and the benefits of surgery more ambiguous. Dilated cardiomyopathy of a given origin causes the morphologically normal valve to leak, and correction of secondary MR will not cure the underlying ventricular disease. Surgery for functional MR mostly in ischemic cardiomyopathy has proven beneficial to some extent, for example, improvement of New York Heart Association (NYHA) functional class [3] or quality of life, but proof of survival benefit is pending. Further, operative risk is elevated as compared with MVR for degenerative MR [4] . It is for this growing population of high-risk patients that less invasive treatment alternatives have been explored, leading to the development and clinical implementation of trans-catheter MVR devices [5] . The MitraClip TM device (Abbott Vascular, Menlo Park, CA, USA) aims to achieve a similar effect as surgical edge-to-edge repair in a beatingheart, catheter-based adaptation. The MitraClip TM achieves approximation of the free edges of the anterior mitral leaflet (AML) and posterior mitral leaflet (PML) by means of a polyester-covered clip that is introduced via the femoral vein and a transseptal route. After antegrade passage of the MV, the clip is opened and pulled back grasping up to 8 mm of the leaflet margins. Closure of the clip arms then results in a 'double-orifice' valve ( Fig. 1 ) and also induces a cinching effect with tension applied to the mitral annulus. Before detachment of the clip from the deployment catheter, MV function can be assessed under physiological hemodynamic conditions. At this point, the clip can still be reopened and repositioned or it can even be completely retrieved. This feature of the MitraClip TM device has been considered advantageous in that it preserves standard-of-care treatment options, that is, surgical MVR [6] . However, damage to the mitral leaflets has been reported to occur either during the intervention, in the postprocedural period, or during clip removal in cases where secondary surgery became necessary [7] . This issue and its impact on the feasibility and success of secondary surgical MVR are currently under debate.
Patients and methods
Of the first consecutive 215 patients treated with the MitraClip TM device, surgical revision became necessary in six cases for failed clip placement (n = 3) or recurrent severe MR (n = 3; 6 of 215, freedom from surgery 97.2%) within a mean follow-up of 344 AE 227 days after trans-catheter MVR. Surgical revision was performed at a mean of 35.8 AE 47.7 (range 0-117) days after trans-catheter MVR. Detailed demographic and intraprocedural data of all cases are provided in Table 1 .
Results

Case report #1
A 47-year-old male patient with advanced dilated cardiomyopathy was evaluated for treatment. Pre-procedural echocardiography revealed MR grade 4+ due to annular dilatation and restrictive PML. Interventional treatment was initiated with the clip delivery system advanced into the left atrium. However, due to severe dilatation of the mitral annulus, grasping of both leaflet margins was not achieved and the procedure aborted. As the patient continued to be in a state of marked hemodynamic compromise, decision was made for elective surgical MVR 4 days later. Standard bicaval and aortic cannulation were performed and access to the MV was gained via a transseptal approach. The mitral annulus diameter was measured at >5 cm with restrictive PML. Downsizing annuloplasty was performed using a 30-mm IMR ring (Edwards Lifesciences, Inc., Irvine, CA, USA). In addition, resection of the left-atrial appendage and tricuspid valve repair with an Edwards Classic 32-mm ring (Edwards Lifesciences, Inc.) were carried out. In the further course of his hospitalization, the patient developed hemodynamically relevant pericardial effusion, necessitating drainage on postoperative day 5. Prior to discharge, transthoracic echocardiography demonstrated residual MR 1+ with no residual tricuspid regurgitation. At the latest follow-up 18 months after surgery, the patient was well with only trace residual MR, no tricuspid regurgitation, and stable leftventricular function at 35-40% ejection fraction under intensified heart-failure medication.
Case report #2
A 58-year-old male patient was referred to our center with severe MR due to Barlow's disease with ruptured PML chords. In addition, he had an ischemic cardiomyopathy with markedly reduced left-ventricular function and had undergone all-arterial triple coronary artery bypass grafting 6 years earlier with patent grafts. MitraClip TM treatment was performed using two clips and acutely resulted in marked reduction of MR severity (residual MR 1+). Two months later, however, the patient was re-admitted with recurrent severe MR and P2/P3 prolapse presumably due to partial clip detachment, as suspected from transthoracic echocardiography. The patient underwent re-entry sternotomy and conventional surgical MVR with triangular resection of prolapsing P2/P3 tissue and annuloplasty using a 38-mm Physio II ring (Edwards Lifesciences, Inc.). The procedure was complicated by pronounced calcification of the posterior mitral annulus. Intra-operatively, one clip was found to be detached from the P3 segment and adherent to the A3 segment only. The second clip was still in correct position adapting P2/A2 segments (Fig. 2 ). Both clips were removed Table 1 . Patient demographics, procedural data and follow-up. logEuroSCORE, logistic EuroSCORE; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; PML, posterior mitral leaflet; ICM, ischemic cardiomyopathy; CABG, coronary artery bypass grafting; LIMA, left internal mammary artery; LAD, left anterior descending; RIMA, right internal mammary artery; OM1, first obtuse marginal branch; D1, first diagonal branch; SVG, saphenous vein graft; RIVP, ramus interventricularis posterior; ASD, atrial septal defect; AHT, arterial hypertension; LAA, left atrial appendage; CM, cardiomyopathy; TR, tricuspid regurgitation; PHT, pulmonary hypertension; COPD, chronic obstructive pulmonary disease; VF, ventricular fibrillation; Afib, atrial fibrillation; IDDM, insulin-dependant diabetes mellitus; CAD, coronary artery disease; ICD, implantable cardioverter defibrillator. without damage to the leaflets. Additional cooled radiofrequency MAZE procedure was performed for atrial fibrillation. The patient made an uneventful recovery and was discharged on day 8 after surgery in sinus rhythm. Follow-up echocardiography 10 months after surgical MVR demonstrated no residual MR and sustained sinus rhythm.
Case report #3
A 57-year-old male patient was admitted with ischemic cardiomyopathy and markedly reduced left-ventricular function. Transthoracic echocardiography revealed severe MR due to bileaflet prolapse. The patient underwent transcatheter MVR with placement of one clip and initial successful reduction to MR grade 1, and a second clipping procedure 11 months later for recurrent MR 3. As the second procedure did not achieve relevant reduction of MR, surgery was planned. Intra-operatively, detachment of one clip from the PML with adherence to the AML only became apparent. Clip removal resulted in a 5 Â 10 mm AML defect as well as a P2/P3 cleft, which was repaired by a Cardionyl 5/0 running suture. Three and two polytetrafluoroethylene (PTFE) Goretex neochords were used to correct AML and PML prolapse, respectively. A 28-mm IMR ring (Edwards Lifesciences, Inc.) was implanted and repair completed by a commissural P3/A3 Alfieri stitch.
In addition, aortic valve replacement was performed for severe regurgitation of the sclerotic aortic valve, using a Solo Freedom 23-mm valve (Sorin Biomedica Cardio, Saluggia, Italy) and tricuspid valve repair due to severe tricuspid regurgitation using a 32-mm Edwards Classic (Edwards Lifesciences, Inc.) annuloplasty ring on the fibrillating heart.
The patient was discharged to a rehabilitation facility 9 days after surgery and is in good condition at the latest follow-up 4 months postoperatively, with no residual MR or TR as well as adequate function of the aortic-valve prosthesis.
Case report #4
A 71-year-old female patient with severe functional MR due to annular dilatation and restrictive PML was referred for MitraClip TM treatment. Grasping of both AML and PML margins was technically demanding, but eventually successful. However, when closing the clip, rupture of an AML chord occurred, presumably due to calcification of chords and papillary muscle heads. As further attempts at clip placement did not seem promising, the clip was retrieved and the procedure terminated. On the following day, the patient underwent elective surgical MVR. Intra-operatively, a primary chord of the A2 segment proved to be ruptured. In addition, a P2/P3 cleft was apparent, likely caused by the attempted clip placement. To restore valve function, a PTFE Goretex neochord (W.L. Gore & Associates, Inc., AZ, USA) was inserted to re-attach the A2 segment. The PML defect was repaired with a 5/0 Cardionyl (Peters Surgical, Bobigny Cedex, France) running suture. Repair was completed by a co-aptation stitch between P3 and A3 segments and annuloplasty using a 28-mm Physio ring (Edwards Lifesciences, Inc.). Concomitant tricuspid regurgitation was corrected by placement of a 36-mm Edwards Classic tricuspid annuloplasty ring (Edwards Lifesciences, Inc.). Postoperative echocardiography confirmed adequate valve function with trace residual MR and no residual tricuspid regurgitation at discharge.
Three months after surgery, the patient was re-admitted with recurring severe MR most likely due to dehiscence of the annuloplasty ring, as suspected from transthoracic echocardiography. As the patient was highly symptomatic, the decision was made for repeat surgery. Intra-operatively, the annuloplasty ring was found detached from the posterior mitral annulus with two clefts near the base of P2. Because of marked valve tissue degeneration and to ensure adequate valve function, valve replacement using a 31-mm Edwards Perimount prosthesis (Edwards Lifesciences, Inc.) was performed. The further intra-and postoperative course was uneventful with discharge 10 days after surgery. The patient is alive and well up to the latest follow-up 22 months after MV replacement.
Case report #5
A 75-year-old female patient was admitted with ischemic cardiomyopathy and severely compromised left-ventricular function after suffering recurrent episodes of acute heart failure. Severe functional MR due to annular dilatation was demonstrated on preoperative echocardiography. Interventional treatment was performed placing two clips, which failed to reduce MR. Intraprocedural TEE suggested injury of the AML. Decision was made for immediate conversion to surgical MVR in the same hybrid operating room. Intra-operatively, the clips were found attached to the P3 segment only. There was a large cleft in A2/A3 segments, presumably caused by clip tear out. Due to this finding, repair was deemed impossible and valve replacement using a 31-mm Edwards Perimount Plus prosthesis (Edwards Lifesciences, Inc.) with concomitant exclusion of the left-atrial appendage was performed. Persistent total atrioventricular conduction block necessitated pacemaker implantation on postoperative day 3. The patient was discharged on day 10 with adequate prosthesis function and is in good condition 8 months after surgery. 
Case report #6
A 74-year-old patient with status post Stanford type-A aortic dissection and replacement of the ascending aorta and hemiarch 21 years earlier, markedly reduced leftventricular function and severe functional MR was referred to our center. Trans-catheter MVR was carried out placing two clips with good acute success and reduction to MR 2. The further postoperative stay was complicated by slow cardiac recompensation with recurrent pleural effusions necessitating repeated drainage. Routine transthoracic echocardiography on day 16 after MitraClip TM treatment revealed recurrent severe MR with a predominantly excentric jet from the PML, suggesting partial clip detachment or clip tear out.
Intra-operatively, extensive damage of the PML became apparent. A large L-shaped cleft was present along the edge of the lateral of the two clips. It was located between P1 and P2 segments extending to the base of the PML and along the mitral annulus. Therefore, decision was made for MV replacement using a 31-mm Hancock II Mitral bioprosthesis (Medtronic Inc., Minneapolis, MN, USA). The further intraoperative course was uneventful. Postoperatively, the patient suffered aggravation of pre-existing renal insufficiency with temporary need for hemodialysis, as well as sigmoid diverticulitis and acute pancreatitis, necessitating re-admission to the intensive care unit. Here he expired on day 6 after surgery, after suffering a thrombembolic cerebral stroke.
Discussion
In the landmark EVEREST I (Endovascular Valve Edge-toEdge REpair Study) trial (ClinicalTrials.gov Identifier: NCT00209339), safety and feasibility of the MitraClip TM system were confirmed in 55 patients [8] . Furthermore, sustained reduction to 2+ MR at 12 months was demonstrated in a recent study in 66% of patients after acute procedural success and in 48% of the intention-to-treat population [9] . In the EVEREST II trial, which has completed enrolment, patients have been randomized to receive treatment with the MitraClip TM system or surgical MVR (ClinicalTrials.gov Identifier: NCT00209274). Twelve-month results were recently reported [10] . Both the superiority hypothesis regarding safety as well as the non-inferiority hypothesis regarding clinical success rate were met according to pre-specified margins. Trial design, however, especially the definition of clinical end points remains a controversial subject.
As of today, our group has acquired the world's largest single-center experience with the MitraClip TM device. Since the initiation of our program in 2008, well over 200 patients have been treated. In contrast to the EVEREST eligibility criteria, the device is being applied exclusively in high-risk patients deemed poor surgical candidates due to relevant comorbidities, as determined by an interdisciplinary heartvalve team consisting of cardiac surgeons and cardiologists. In an interim analysis, favorable acute outcomes were reported in the first 51 consecutive patients without major periprocedural morbidity and no in-hospital mortality [11] .
To date, most available reports on MV surgery after MitraClip TM therapy stem from the EVEREST experience in low-risk patients. Feasibility of surgical MVR after failed trans-catheter MVR with the MitraClip TM device in elective patients with mostly degenerative MV disease was reported for the majority of patients in these studies. However, as of yet there are no reports on the effect of MitraClip TM therapy on secondary MV surgery in high-risk patients with predominantly functional MR.
Dang and colleagues reported on six patients from the early EVEREST I study experience in whom surgery became necessary after prior trans-catheter MVR [6] . All patients had myxomatous disease with preserved left-ventricular function. Reasons for surgical revision were malpositioning with subsequent partial detachment of clips in four patients and insufficient reduction of MR in two cases. Secondary surgical MVR was successful in five patients, while intended MV replacement was performed in one case. In their experience, removal of clips was unproblematic and did not influence the initial surgical strategy.
In another series, Rogers and colleagues report on four cases of late surgical MVR after prior MitraClip TM therapy [12] . Recurrent MR after interventional treatment necessitated surgical revision, which was successfully carried out after up to 5 years after trans-catheter MVR. Although the clips were described as heavily encapsulated in fibrous tissue in most patients, removal was possible without extensive leaflet damage, allowing for valve repair in all four cases.
In the largest series to date, Argenziano and colleagues recently reported outcomes of 32 patients (19 patients from the EVEREST I trial and 13 EVEREST II roll-in patients) undergoing surgery after previous MitraClip treatment [13] . Of these, 23 patients had at least one clip implanted; the remaining nine patients had not received an implant. The optimal surgical strategy had been assessed retrospectively (EVEREST I) or prospectively (EVEREST II), according to trial requirements. Surgical revision was carried out as initially planned before trans-catheter MVR in 27 of 31 patients (87%). Overall, 67% (21 of 32) of patients had MVR and 33% (11 of 32) had MV replacement. Of the latter, six replacements had been planned preoperatively, four patients were converted from repair to replacement, and, in one patient, the initial surgical strategy was unknown. Only in two patients, damage to MV leaflets was reported, in one case explicitly related to the clip procedure. The authors conclude that surgical options as planned before clip procedures are preserved in the majority of cases.
In contrast to previous series, we report our experience of secondary MV surgery in high-risk patients. In three cases, secondary surgical MVR was feasible without a major change in the surgical strategy deemed optimal before transcatheter MVR: in case #1, trans-catheter MVR had been aborted before clip placement and therefore did not influence secondary MV surgery and in case #2, clip removal was unproblematic. In case #3, clip removal resulted in a small AML defect as well as a PML cleft, which was however easily repaired by a running suture.
In three other cases, however (cases #4, #5, and #6), prior trans-catheter MVR influenced secondary MV surgery. In case #4, chordal rupture and injury of the PML necessitated more complex surgical MVR with implantation of an AML neochord and PML cleft repair, as opposed to annuloplasty alone. Although valve repair was initially successful, during the further follow-up, MV replacement became necessary for recurrent severe MR due to partial ring detachment from a calcified posterior annulus but unrelated to prior clip therapy. In case #5, a large defect in segments A2/A3 precluded valve repair and led to MV replacement, where annuloplasty had been the initially proposed surgical strategy. In case #6 a large PML cleft made valve repair impossible and led to prosthetic valve replacement.
Conclusions
In our experience, the MitraClip TM system is a promising additional tool for the treatment of high-risk patients with limited surgical options. The favorable risk-benefit ratio of MitraClip TM treatment with low periprocedural complication rates underscores its adequacy for high-risk patients in whom even a result considered suboptimal from a surgeon's point of view may offer substantial clinical improvement. However, it is our firm belief that trans-catheter MVR should remain restricted to high-risk patients, especially as secondary surgical MVR may not always be feasible after prior MitraClip TM treatment as demonstrated in our series. Furthermore, MVR may require more complex techniques due to prior MitraClip TM treatment and impact on long-term durability of surgical MVR in these cases is unknown. Given the rising caseload of transcatheter MV therapy across European centers, it can be anticipated that surgeons will be confronted with increasing numbers of patients with recurrent MR after MitraClip TM treatment or after failed procedures. In an ideal setting, potential candidates for trans-catheter MVR should be assessed in an interdisciplinary conference of cardiologists and cardiac surgeons to determine the optimal treatment strategy for each patient -surgical or interventional.
